GPD2 inhibition impairs coagulation function via ROS/NF-κB/P2Y12 pathway.

ABSTRACT:

Background

Coronary heart disease (CHD) remains a global health threat. As antiplatelet therapy constitutes the cornerstone of CHD management, ticagrelor has been universally endorsed as a first-line agent in major clinical guidelines. However, the therapeutic efficacy of ticagrelor is compromised by interindividual variability in bleeding risk. Notably, while inherited genetic variations account for part of this heterogeneity, the dynamic regulatory role of modifiable epigenetic mechanisms-particularly DNA methylation in mediating platelet reactivity-remains inadequately characterized, presenting a critical knowledge gap in optimizing precision antiplatelet strategies.

Methods

We utilized the 850k methylation array to measure DNA methylation levels in blood samples from 47

SUBMITTER: Chen J 

PROVIDER: S-EPMC12273321 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature